+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-invasive Prenatal Testing Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446110
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • Agilent Technologies Inc
  • BGI Diagnosis
  • EUROFINS Genoma Group
  • GE Healthcare
  • LifeCodexx AG
  • Next Biosciences
Non-invasive Prenatal Testing Global Market Report 2021: COVID-19 Growth and Change to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global non-invasive prenatal testing market.







The report focuses on the non-invasive prenatal testing market which is experiencing strong growth. The report gives a guide to the non-invasive prenatal testing market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for non-invasive prenatal testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Non-invasive Prenatal Testing Market Global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope


Markets Covered:


  • By Type: Consumables; Instruments
  • By End User: Hospital; Diagnostic Labs
  • By Instruments: NGS Systems; PCR Instruments; Microarrays; Ultrasound Devices; Others(Centrifuges; UV Systems; Incubators; Microscopes)
  • By Consumables: Assay Kits & Reagents; Disposables
  • By Application: Trisomy; Microdeletion; Genetics; Rh factor

Companies Mentioned:


F. Hoffmann-La Roche AG; Illumina; Laboratory Corporation of America Holdings; Natera; PerkinElmer

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data Segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Non-Invasive Prenatal Testing Market

What is the estimated value of the Global Non-Invasive Prenatal Testing Market?

The Global Non-Invasive Prenatal Testing Market was estimated to be valued at $2.4 billion in 2021.

What is the growth rate of the Global Non-Invasive Prenatal Testing Market?

The growth rate of the Global Non-Invasive Prenatal Testing Market is 13.4%, with an estimated value of $4.0 billion by 2025.

What is the forecasted size of the Global Non-Invasive Prenatal Testing Market?

The Global Non-Invasive Prenatal Testing Market is estimated to be worth $4.0 billion by 2025.

Who are the key companies in the Global Non-Invasive Prenatal Testing Market?

Key companies in the Global Non-Invasive Prenatal Testing Market include F. Hoffmann, La Roche AG, IlluminaInc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc and Berry Genomics Co., Ltd.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies Inc
  • BGI Diagnosis
  • EUROFINS Genoma Group
  • GE Healthcare
  • LifeCodexx AG
  • Next Biosciences

1. Executive Summary2. Non-invasive Prenatal Testing Market Characteristics3. Non-invasive Prenatal Testing Market Trends and Strategies4. Impact Of COVID-19 On Non-invasive Prenatal Testing
5. Non-invasive Prenatal Testing Market Size and Growth
5.1. Global Non-invasive Prenatal Testing Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Non-invasive Prenatal Testing Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Non-invasive Prenatal Testing Market Segmentation
6.1. Global Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Consumables
  • Instruments
6.2. Global Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital
  • Diagnostic Labs
6.3. Global Non-invasive Prenatal Testing Market, Segmentation by Instruments, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • NGS Systems
  • PCR Instruments
  • Microarrays
  • Ultrasound Devices
  • Others(Centrifuges
  • UV systems
  • Incubators
  • Microscopes
6.4. Global Non-invasive Prenatal Testing Market, Segmentation by Consumables, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Assay Kits &Reagents
  • Disposables
6.5. Global Non-invasive Prenatal Testing Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Trisomy
  • Microdeletion
  • Genetics
  • Rh factor

7. Non-invasive Prenatal Testing Market Regional and Country Analysis
7.1. Global Non-invasive Prenatal Testing Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Non-invasive Prenatal Testing Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Non-invasive Prenatal Testing Market
8.1. Asia-Pacific Non-invasive Prenatal Testing Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Non-invasive Prenatal Testing Market
9.1. China Non-invasive Prenatal Testing Market Overview
9.2. China Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Non-invasive Prenatal Testing Market
10.1. India Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Non-invasive Prenatal Testing Market
11.1. Japan Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Non-invasive Prenatal Testing Market
12.1. Australia Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Non-invasive Prenatal Testing Market
13.1. Indonesia Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Non-invasive Prenatal Testing Market
14.1. South Korea Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Non-invasive Prenatal Testing Market
15.1. Western Europe Non-invasive Prenatal Testing Market Overview
15.2. Western Europe Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Non-invasive Prenatal Testing Market
16.1. UK Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Non-invasive Prenatal Testing Market
17.1. Germany Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Non-invasive Prenatal Testing Market
18.4. France Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Non-invasive Prenatal Testing Market
19.1. Eastern Europe Non-invasive Prenatal Testing Market Overview
19.2. Eastern Europe Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Non-invasive Prenatal Testing Market
20.1. Russia Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Non-invasive Prenatal Testing Market
21.1. North America Non-invasive Prenatal Testing Market Overview
21.2. North America Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Non-invasive Prenatal Testing Market
22.1. USA Non-invasive Prenatal Testing Market Overview
22.2. USA Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Non-invasive Prenatal Testing Market
23.1. South America Non-invasive Prenatal Testing Market Overview
23.2. South America Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Non-invasive Prenatal Testing Market
24.1. Brazil Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Non-invasive Prenatal Testing Market
25.1. Middle East Non-invasive Prenatal Testing Market Overview
25.2. Middle East Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Non-invasive Prenatal Testing Market
26.1. Africa Non-invasive Prenatal Testing Market Overview
26.2. Africa Non-invasive Prenatal Testing Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Non-invasive Prenatal Testing Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Non-invasive Prenatal Testing Market Competitive Landscape and Company Profiles
27.1. Non-invasive Prenatal Testing Market Competitive Landscape
27.2. Non-invasive Prenatal Testing Market Company Profiles
27.2.1. F. Hoffmann-La Roche AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Illumina, Inc.
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Laboratory Corporation of America Holdings
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Natera, Inc.
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. PerkinElmer, Inc.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Key Mergers and Acquisitions in the Non-invasive Prenatal Testing Market29. Non-invasive Prenatal Testing Market Future Outlook and Potential Analysis
30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
30.4. About the Publisher
30.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies Inc
  • BGI Diagnosis
  • EUROFINS Genoma Group
  • GE Healthcare
  • LifeCodexx AG
  • Next Biosciences
Major players in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc. and PerkinElmer Inc.

The global non-invasive prenatal testing market is expected to grow from $2.17 billion in 2020 to $2.43 billion in 2021 at a compound annual growth rate (CAGR) of 12%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.02 billion in 2025 at a CAGR of 13.4%.

The non-invasive prenatal testing market consists of sales of non-invasive prenatal testing kits, instruments and related services. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects in fetus in first trimester of pregnancy. Non-invasive prenatal testing includes ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests and biochemical screening tests.

The non-invasive prenatal testing market covered in this report is segmented by type into consumables, instruments. It is also segmented by end user into hospital, diagnostic labs; by instruments into NGS systems, PCR instruments, microarrays, ultrasound devices, others(centrifuges, UV systems, incubators, microscopes); by consumables into assay kits &reagents, disposables and by application into trisomy, microdeletion, genetics, Rh factor.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The ethical hurdles in the non-invasive prenatal testing (NIPT) market have led to a range of ethical issues in terms of sex selection or aborting babies with chromosomal abnormality. Determining the sex of the fetus or knowing if the baby has an abnormality at an earlier stage led to abortions and resulted as an ethical issue which further led to strict regulations on using such devices. According to Department of Health (UK), there were 3,213 abortions in England and Wales from which 37% of the total abortions consisted of chromosomal abnormality and 80% of the abortions were performed under 10 weeks of pregnancy. These hurdles will restrain the non-invasive prenatal testing market.

Next generation sequencing has increased the throughput, scalability, and speed, and further enables researchers to perform a wide range of applications and study biological systems at a higher level. Next generation sequencing is a platform that has enabled sequencing of thousands to millions of DNA molecules simultaneously. The manufacturers have introduced this technology to reduce the time and money required and optimizes the output to generate results regarding genome, DNA testing. Major companies such as Illumina, Eurofins, Natera, Roche, and Annoroad have implemented this technology in non-invasive prenatal testing. CFDA (China Food and Drug Administration) has approved the medical instrument product registration of NGS instrument NextSeq 550AR produced by Annoroad.

In June 2019, Invitae, a USA based medical genetics company acquired Singular Bio for $55M. This acquisition will further strengthen Invitae's ability to bring genetic information into mainstream medical care. Singular Bio, a USA based company specializing in single-molecule, cell-free DNA analysis that it is developing for non-invasive prenatal testing.

High incidence rate of Down syndrome is one major factor driving non-invasive prenatal testing (NIPT) market with increase in average maternal age which has led to a concern on the safety about the growth of the fetus. Down syndrome is a chromosomal condition that occurs when an error in cell division results in an extra chromosome 21 and can affect the fetus cognitive ability and physical growth. The NIPT screening tests do not harm the mother or baby, carries no risk of miscarriage as they are non-invasive, and can detect more than 99% of cases of Down syndrome. According to National Down Syndrome Society and Centres for Disease control and Prevention, in the USA, 1 in every 700 babies are born with Down syndrome and 80% of children with Down syndrome are born to older mothers. The increased risk of having babies with Down syndrome among older women drives the non-invasive prenatal testing market.

The non-invasive prenatal testing market is regulated by several regulations that are governed by multiple international and country specific agencies. For instance, the US Food and Drug Administration (FDA) that issues Laboratory Developed Tests (LDTs) certification and Clinical Laboratory Improvement Amendments (CLIA) certification. The manufacturer needs to obtain a 510(k) premarket notification for in vitro diagnostic test. LDTs and CLIA certification are based on number of tests done during clinical trials. For example: For trisomy 21 (Down syndrome), there is an incidence of 1/1000. Given a target of 100 positive results, at least 100,000 samples would have to be tested to meet the requirements of a 510k. A 510k premarket notification demonstrates that the new product is at least as safe and effective as another legally-marketed device. It is mandatory for manufacturers to register a premarket notification before a new product can be certified as fit for market commercially.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • F. Hoffmann-La Roche AG
  • IlluminaInc.
  • Laboratory Corporation of America Holdings
  • Natera Inc.
  • PerkinElmer Inc.
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc
  • BGI Diagnosis
  • Berry Genomics Co., Ltd
  • LifeCodexx AG
  • Myriad GeneticsInc.
  • NIPD Genetics
  • Sequenom Inc.
  • Annoroad Gene Technology
  • Centogene AG
  • Counsyl Inc.
  • EUROFINS Genoma Group
  • Eurofins Scientific
  • Next Biosciences
  • Premaitha Health Plc
  • Ariosa Diagnostics (Roche)
  • Premaitha Health
  • Beijing Genomics Institute
  • Yourgene Health PLC
  • GE Healthcare
  • Koninklijke Philips N.V.
  • Thermo Fisher Scientific Inc.
  • Pacific Biosciences of California Inc.
  • QIAGEN N.V.
Note: Product cover images may vary from those shown

Loading
LOADING...